Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2017 | 25 | 0.70 | Why? |
| Vitamin K Epoxide Reductases | 1 | 2017 | 32 | 0.68 | Why? |
| Indians, South American | 1 | 2017 | 126 | 0.64 | Why? |
| Anopheles | 3 | 2019 | 89 | 0.50 | Why? |
| Warfarin | 1 | 2017 | 402 | 0.49 | Why? |
| Leptin | 3 | 2019 | 141 | 0.48 | Why? |
| Brazil | 21 | 2021 | 12582 | 0.42 | Why? |
| Receptors, Leptin | 3 | 2019 | 12 | 0.41 | Why? |
| Prisoners | 1 | 2017 | 738 | 0.37 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.33 | Why? |
| Mosquito Vectors | 2 | 2019 | 351 | 0.30 | Why? |
| Aedes | 2 | 2018 | 380 | 0.28 | Why? |
| Insect Vectors | 2 | 2018 | 227 | 0.26 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.22 | Why? |
| Genome, Insect | 2 | 2017 | 5 | 0.22 | Why? |
| Receptor, Melanocortin, Type 4 | 1 | 2018 | 2 | 0.19 | Why? |
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2018 | 25 | 0.19 | Why? |
| Insect Bites and Stings | 1 | 2019 | 63 | 0.18 | Why? |
| Sterilization, Reproductive | 1 | 2017 | 13 | 0.18 | Why? |
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2017 | 1 | 0.18 | Why? |
| Leishmaniasis, Visceral | 1 | 2018 | 85 | 0.17 | Why? |
| Salivary Proteins and Peptides | 1 | 2017 | 12 | 0.17 | Why? |
| Malaria, Vivax | 1 | 2019 | 152 | 0.17 | Why? |
| DNA Transposable Elements | 1 | 2017 | 91 | 0.17 | Why? |
| Dengue | 3 | 2018 | 1565 | 0.16 | Why? |
| Information Systems | 1 | 2017 | 110 | 0.16 | Why? |
| Sentinel Surveillance | 2 | 2021 | 1093 | 0.15 | Why? |
| Cities | 4 | 2021 | 4937 | 0.15 | Why? |
| Multigene Family | 1 | 2017 | 377 | 0.15 | Why? |
| Carcinoma, Ductal, Breast | 1 | 2017 | 149 | 0.15 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.15 | Why? |
| Disease Notification | 2 | 2020 | 639 | 0.14 | Why? |
| Yellow Fever | 1 | 2018 | 231 | 0.14 | Why? |
| Culicidae | 2 | 2017 | 239 | 0.14 | Why? |
| Rotavirus Vaccines | 1 | 2017 | 203 | 0.14 | Why? |
| Nuclear Proteins | 1 | 2017 | 321 | 0.14 | Why? |
| Carrier Proteins | 1 | 2017 | 513 | 0.13 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2016 | 231 | 0.13 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.13 | Why? |
| Wolbachia | 1 | 2012 | 9 | 0.13 | Why? |
| Pest Control, Biological | 1 | 2012 | 11 | 0.13 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.12 | Why? |
| Rotavirus Infections | 1 | 2017 | 355 | 0.12 | Why? |
| Polymorphism, Genetic | 2 | 2018 | 1074 | 0.12 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.12 | Why? |
| Lipids | 1 | 2019 | 1079 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 694 | 0.12 | Why? |
| Dog Diseases | 1 | 2018 | 745 | 0.11 | Why? |
| Air Travel | 1 | 2018 | 585 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.10 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.10 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.10 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.10 | Why? |
| Postpartum Period | 1 | 2016 | 936 | 0.10 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.10 | Why? |
| Models, Theoretical | 4 | 2020 | 6659 | 0.10 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.10 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Seroepidemiologic Studies | 5 | 2021 | 10017 | 0.09 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.09 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.08 | Why? |
| Probability | 3 | 2020 | 923 | 0.08 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.08 | Why? |
| Basic Reproduction Number | 1 | 2019 | 2676 | 0.08 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.08 | Why? |
| Diet | 1 | 2018 | 2052 | 0.07 | Why? |
| Blood Pressure | 1 | 2016 | 2198 | 0.07 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.07 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.07 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.07 | Why? |
| Fuzzy Logic | 1 | 2003 | 75 | 0.06 | Why? |
| Incidence | 4 | 2018 | 25622 | 0.06 | Why? |
| Body Mass Index | 1 | 2016 | 4306 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Health Policy | 2 | 2020 | 6242 | 0.06 | Why? |
| Humans | 28 | 2021 | 930598 | 0.06 | Why? |
| Social Class | 2 | 2021 | 1360 | 0.06 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.06 | Why? |
| Pregnancy | 3 | 2019 | 23879 | 0.06 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.06 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.06 | Why? |
| Alleles | 2 | 2018 | 1557 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.06 | Why? |
| Female | 15 | 2021 | 380317 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Dogs | 2 | 2018 | 2529 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Epidemiologic Methods | 1 | 2003 | 392 | 0.05 | Why? |
| Euthanasia, Animal | 1 | 2018 | 2 | 0.05 | Why? |
| Family Characteristics | 2 | 2020 | 2551 | 0.05 | Why? |
| Latin America | 2 | 2017 | 1721 | 0.05 | Why? |
| Child | 7 | 2021 | 70012 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Health Information Systems | 1 | 2020 | 130 | 0.05 | Why? |
| Adult | 10 | 2021 | 244371 | 0.05 | Why? |
| Antibodies, Protozoan | 1 | 2018 | 121 | 0.04 | Why? |
| Dietary Carbohydrates | 1 | 2018 | 64 | 0.04 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.04 | Why? |
| Plasmodium vivax | 1 | 2019 | 154 | 0.04 | Why? |
| Animals | 8 | 2019 | 78931 | 0.04 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| DNA Repair | 1 | 2017 | 114 | 0.04 | Why? |
| Americas | 1 | 2018 | 418 | 0.04 | Why? |
| Infant | 4 | 2021 | 30274 | 0.04 | Why? |
| Risk | 2 | 2020 | 5288 | 0.04 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.04 | Why? |
| Bronchitis | 1 | 2017 | 146 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2019 | 3607 | 0.04 | Why? |
| Molecular Sequence Annotation | 1 | 2017 | 478 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Geographic Information Systems | 1 | 2018 | 507 | 0.03 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.03 | Why? |
| Disease Eradication | 1 | 2020 | 581 | 0.03 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.03 | Why? |
| Blood Pressure Determination | 1 | 2016 | 450 | 0.03 | Why? |
| Spatial Analysis | 1 | 2018 | 878 | 0.03 | Why? |
| Colombia | 1 | 2017 | 1241 | 0.03 | Why? |
| Aged | 5 | 2021 | 215776 | 0.03 | Why? |
| Population Density | 1 | 2017 | 694 | 0.03 | Why? |
| Gastroenteritis | 1 | 2017 | 489 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Alphavirus Infections | 1 | 2012 | 68 | 0.03 | Why? |
| Gene Frequency | 1 | 2016 | 1210 | 0.03 | Why? |
| Immunization | 1 | 2021 | 2019 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2017 | 952 | 0.03 | Why? |
| Animals, Wild | 1 | 2018 | 1028 | 0.03 | Why? |
| Travel | 2 | 2020 | 7220 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.03 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.02 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.02 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.02 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Chikungunya Fever | 1 | 2012 | 345 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 11367 | 0.02 | Why? |
| Mothers | 1 | 2018 | 1624 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Schools | 1 | 2020 | 4187 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.02 | Why? |
| Internationality | 1 | 2017 | 3297 | 0.02 | Why? |
| Internet | 1 | 2021 | 6204 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2017 | 3691 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| Malaria | 1 | 2012 | 1097 | 0.01 | Why? |
| Computational Biology | 1 | 2017 | 4514 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2016 | 17020 | 0.01 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 533 | 0.01 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.01 | Why? |
| Decision Support Techniques | 1 | 2003 | 903 | 0.01 | Why? |
| Measles | 1 | 2003 | 608 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Computer Simulation | 1 | 2003 | 4982 | 0.01 | Why? |
Struchiner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(120)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_